To test the hypothesis that clozapine-induced reduction of glutamate transporter-1 (GLT-1) expression is mediated by astrocytes, we studied the effects of clozapine on Glu transporters and Glu uptake in primary astrocyte cultures of the cerebral cortex. Astrocyte cultures treated for 48 h with clozapine exhibited a reduction in GLT-1 levels of about 50%, whereas glutamate-aspartate transporter (GLAST) levels remained unchanged. Glu uptake was also lowered, and this reduction was dose-dependent. Our findings indicate that clozapine reduces GLT-1 expression and function by a mechanism that directly involves astrocytes. A better understanding of the molecular events by which antipsychotics regulate Glu uptake can contribute to identify new targets for the treatment of schizophrenia. High-affinity uptake is the major mechanism by which the CNS regulates the extracellular levels of glutamate (Glu), the main excitatory neurotransmitter in the cerebral cortex (Conti and Hicks, 1996) . To date, five different Glu transporters (GluTs) have been cloned, the neuronal EAAC1 and the astrocytic glutamate aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) being the major subtypes (Conti and Weinberg, 1999; Danbolt, 2001) .
High-affinity uptake is the major mechanism by which the CNS regulates the extracellular levels of glutamate (Glu), the main excitatory neurotransmitter in the cerebral cortex (Conti and Hicks, 1996) . To date, five different Glu transporters (GluTs) have been cloned, the neuronal EAAC1 and the astrocytic glutamate aspartate transporter (GLAST) and glutamate transporter-1 (GLT-1) being the major subtypes (Conti and Weinberg, 1999; Danbolt, 2001) .
We showed previously that chronic treatment with clozapine reduces Glu uptake in rat frontal cortex considerably, thereby raising extracellular Glu levels, and that this effect is mediated by a selective reduction of GLT-1 (Melone et al., 2001 (Melone et al., , 2003 . The mechanism(s) underlying this novel effect of clozapine is unknown. However, the low levels of GLT-1 expression and function detected in the presence of high Glu levels suggest that the latter effect is secondary to the former, and that the drug's primary site of action are thus the cellular elements expressing GLT-1. Although most studies have shown that GLT-1 is expressed exclusively by astrocytes (Danbolt, 2001) , it was recently suggested that, in certain brain regions, some neurons express GLT-1 (see recent data and literature in Chen et al., 2004) , raising the possibility that the effects of clozapine may be mediated by a differential action on neuronal or astrocytic GLT-1.
The aim of the present experiments was to test the hypothesis that the effects of clozapine on GLT-1 expression and function and on Glu levels are mediated by astrocytes. To do this, we investigated whether the effects of clozapine on GluTs and Glu uptake reported in our previous in vivo studies also take place in primary astrocyte cultures.
Primary astrocyte cultures were established from the cerebral cortex of 1-day-old Sprague-Dawley rats and prepared as described (Swanson et al., 1997) . To promote astrocyte differentiation, confluent cultures were treated with 200 mM dibutyryl cyclic adenosine monophosphate (dBcAMP) for 6 days. Subsequently, astrocytes were treated with 5-50 mM clozapine for 48 h and used for immunochemistry or uptake studies. Viability assays to evaluate putative clozapine toxicity in astrocyte cultures were carried out using the MTT method.
For immunocytochemistry, cells were washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 20 min, permeabilized in methanol at À208C for 10 min, and preincubated with 4% normal goat serum (NGS) in PBS (1 h). Immunostaining for GluTs was carried out with antibodies generously provided by Drs. N.C. Danbolt (GLAST, 1 mg/ml) and J.D. Rothstein (GLT-1, 0.05 mg/ml; EAAC1, 0.1 mg/ml). Glial fibrillary acidic protein (GFAP) antibodies (Dako Diagnósticos S.A., Barcelona, Spain; 20 mg/ml) were used for culture characterization. Incubation with primary antibodies was performed overnight at 48C, and detection was carried out with a fluorescein isothiocyanate (FITC)-conjugated goat antirabbit IgG (Alexa 488; 1:200; Molecular Probes, Eugene, OR).
Glu uptake was measured as described previously (Domercq et al., 1999) . Briefly, astrocytes were incubated for 10 min at 378C with 100 nM of L-[ 3 H]-glutamic acid (Amersham Pharmacia Biotech, Little Chalfont, UK) in a saline solution containing unlabeled glutamic acid (100 mM). Nonspecific uptake was measured by substituting NaCl for choline chloride. All results are expressed as mean 6SEM. Statistical comparisons are made by one-tailed paired Student's t-test.
GluT protein levels were determined in homogenates of astrocytes. Samples (10 mg per lane) were loaded and size separated in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were blotted onto nitrocellulose filters (Amersham Pharmacia Biotech, Madrid, Spain) and incubated with antibodies against GLAST, GLT-1, or EAAC1 (1 mg/ml), and b-actin (1:1,000; Sigma, St. Louis, MO, A2066). Immunoblot labeling was visualized using enhanced chemiluminescence (Pierce, Rockford, IL). Protein band densitometry was performed using Scion Image for Windows (Scion, Frederick, MD), and actin immunoreactivity was used to normalize the GluTs signal.
In astrocytic cultures derived from cerebral cortex, undifferentiated cells expressed only GLAST; treatment with dBcAMP increased GLAST and induced GLT-1 expression (Fig. 1A) . EAAC1 was detected neither in normal astrocyte cultures nor in those treated with dBcAMP. Glu uptake in dBcAMP-treated astrocyte cultures was twice the uptake in control cultures (Fig. 1B) , in line with previous results (Swanson et al., 1997) . MTT viability assays showed that this antipsychotic is not toxic to astrocytes at concentrations of 100 mM after 48 h of exposure (data not shown). At these concentrations, clozapine did not affect astrocyte morphology or GFAP expression ( Fig. 2A) .
We then examined GluT expression by immunocytochemical and immunoblotting techniques after clozapine incubation for 48 h. GLAST and EAAC1 protein levels were unaffected by clozapine treatment, whereas GLT-1 expression was markedly reduced Fig. 1 . Effects of dBcAMP on the expression and function of GluTs in astrocyte cultures. A: Brightfield (top row) and immunofluorescence with antibodies against GFAP, GLAST, and GLT-1 in control and dBcAMP-treated cultures. Note the low expression of the transporters, particularly of GLT-1, in control cultures. Expression of GLAST and GLT-1 increased substantially in astrocytes treated with dBcAMP for 6 days. B: Glu uptake increased in astrocytes stimulated with dBcAMP. **P < 0.001; (one-tailed paired Student's t-test). Scale bars = 100 mm in first row in A; 50 mm in remaining rows.
( Fig. 2A,B) . Functional assays in primary astrocyte cultures treated with 5-50 mM clozapine showed a prominent (>50%), dose-dependent decrease in Na (Fig. 3 ). The present in vitro studies show that GLT-1 expression is markedly reduced by clozapine in astrocyte cultures, indicating that astrocytes may be sufficient to explain the clozapine-induced reduction of GLT-1 expression and Glu uptake described in vivo (Melone et al., 2001 (Melone et al., , 2003 . The recent report by Chen et al. (2004) that in animals perfused without glutaraldehyde only 65-70% of immunoreactivity is astrocytic (the rest being neuronal) raises the possibility that the changes reported in our previous studies (Melone et al., 2001 (Melone et al., , 2003 may depend on altered neuronal GLT-1 expression. Since the reduction observed here is comparable to that reported in vivo (Melone et al., 2001) , the present results demonstrate that the large majority of the effects of clozapine on Glu uptake are mediated by astrocytes. They also confirm the hypothesis that GLT-1 downregulation is the main, although not necessarily the sole, determinant of the raised extracellular Glu levels observed in vivo.
The mechanisms by which clozapine regulates GLT-1 expression in astrocytes remains to be elucidated. GLT-1 expression is driven by positive and negative regulators that modulate promoter activity and transcription through pathways involving NF-kB, Akt, and ERK kinases. Among them, tumor necrosis factor-a (TNF-a), which can be secreted by astrocytes, is a strong repressor of GLT-1 expression (Su et al., 2003) . Interestingly, clozapine raises the plasma levels of TNF-and soluble TNF receptors p55 and p75 in schizophrenic patients (Pollmä cher et al., 1996) . Alternatively, the action of clozapine on GLT-1 expression may be the consequence of the blockade of neurotransmitter receptors, such as dopamine and serotonin receptors (Stahl, 1999) , which are expressed in astrocytes (Bal et al., 1994; Maxishima et al., 2001 ).
In conclusion, we showed that clozapine reduces the expression of GLT-1 and thus Glu uptake in astrocyte cultures; such previously unrecognized feature of this atypical antipsychotic can be relevant to its therapeutic properties as well as to the role of astrocytes in schizophrenia (Coyle and Schwarcz, 2000) . EAAC1 protein was not detectable, whereas b-actin levels were unchanged in CZP-treated cultures. Histogram showing that GLAST levels are not affected by CZP, while GLT-1 protein is reduced by about 50% (n = 4). *P < 0.05; (one-tailed paired Student's t-test). Fig. 3 . Modulation of Glu transport by clozapine in dBcAMP-stimulated astrocytes. CZP inhibits Glu uptake in a dose-dependent manner. Results are means 6SEM of three experiments carried out in triplicate and are expressed as percentage of control. *P < 0.05, **P < 0.001; (one-tailed paired Student's t-test).
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